The preponderance of SGLT‐2 inhibitor use was most evident in the HF risk category, with nearly half (42.4%) of incident type 2 diabetes patients in 2022 who had initiated any medication using a SGLT‐2 inhibitor within 1 year (Figure 3). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.